Coopting Germline BRCA2 Mutation With an Available PARP Inhibitor to Manage Resistance to EGFR Targeted Therapy in EGFR-Mutated Lung Cancer: Combination of Olaparib With Osimertinib.
0/5 보강
APA
Kwon H, Viray H, et al. (2026). Coopting Germline BRCA2 Mutation With an Available PARP Inhibitor to Manage Resistance to EGFR Targeted Therapy in EGFR-Mutated Lung Cancer: Combination of Olaparib With Osimertinib.. Clinical lung cancer, 27(3), 12-16. https://doi.org/10.1016/j.cllc.2026.02.005
MLA
Kwon H, et al.. "Coopting Germline BRCA2 Mutation With an Available PARP Inhibitor to Manage Resistance to EGFR Targeted Therapy in EGFR-Mutated Lung Cancer: Combination of Olaparib With Osimertinib.." Clinical lung cancer, vol. 27, no. 3, 2026, pp. 12-16.
PMID
41861461
같은 제1저자의 인용 많은 논문 (5)
- A pH-Sensitive Sprayable Fluorescent Probe Enables Accurate Visualization of Thyroid Cancer Margins for Fluorescence-Guided Surgery in Orthotopic Mouse Models.
- Artificial intelligence-assisted breast ultrasound: modest AUROC improvement and shorter interpretation time without significant change in diagnostic accuracy.
- Impact of microscopic margin involvement on recurrence of papillary thyroid carcinoma.
- Customized Reconstruction of Lower Eyelid Defects.
- Nonalcoholic Fatty Liver Disease and the Risk of Thyroid Cancer Among Young Adults in South Korea.